Last update Jan. 5, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Hyperprolactinemia; Prolactinoma; Pituitary Adenoma is also known as Hypergalactia; Hyperlactation.
Hyperprolactinemia; Prolactinoma; Pituitary Adenoma belongs to this group or family:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Hypergalactia or hyperlactation is the excessive production of breast milk, with a volume greater than that necessary for the infant to grow normally. There may be physical and social discomfort, fullness and pain in the breast, frequent milk leakage, duct obstruction, vasospasm and mastitis. Infants may have choking, breast refusal, excessive weight gain or weight loss.... All of these can lead to cessation of lactation.
The causes of hypergalactia can be due to hyperstimulation of the breast, idiopathic (of unknown cause) or due to hyperprolactinemia, whether or not due to prolactinomas.
There is no good quality evidence on the best treatment of hypergalactinemia. The following progressive actions are recommended in a stepwise fashion. (Johnson 2020, Trimeloni 2016):
HYPERPROLACTINEMIA and PROLACTINOMES
Breastfeeding does not pose a risk of prolactinoma growth, nor does it increase the recurrence of hyperprolactinemia, whether or not due to micro or macro prolactinomas (Aguayo 2014, Auriemma 2013, Shahzad 2012, Bronstein 2005). Remission of prolactinomas after pregnancy and lactation is frequent (Domingue 2014). There is consensus from expert societies that prolactinomas, micro or macro, do not contraindicate breastfeeding (Casanueva 2006). If they give compression symptomatology they can be treated with dopaminergic agonists. (Aguayo 2014)
Successful and prolonged lactation has been described in more than 30 cases of hypergalactia-prolactinoma-hyperprolactinemia treated with a daily dose of 2.5 to 5 mg of bromocriptine without adverse effects in the infants. (Liu 2018, Verma 2006, Cheng 1996, Canales 1981, Peters 1985)